Social listening can help all along the value chain—from research and discovery to developing marketing plans and strategy.
Despite conventional wisdom that the 23andMe business breakthrough is the direct-to-consumer model, it's also the consolidation of genetic testing, diagnosis and drug development that has the potential to change the industry.
Healthcare spending rose in 2014; Publicis reorganizes its agency network; proposed New Jersey bill would punish drugmakers that move abroad
Healthcare may seem to have been unscarred by the ongoing rash of high-profile cyber-attacks, at least compared with retail and financial organizations. But to hear security pros tell it, the industry is increasingly finding itself as much of a target as companies in other sectors—if not more of one. Karen Epper Hoffman surveys the potential damage
Specialty medicines will keep drug spend trending upward through the next five years.
If more physicians begin participating in late-phase research efforts—and work to educate patients about these opportunities—we can expect new innovations in treatment solutions to come more quickly to market.
Soon, IBM says, Watson will be used by one particular pharma company to create a website where, once a drug is prescribed, patients can ask questions in their own words and the website will provide answers in near real-time.
A pair of surveys paint a complicated picture of what direction pharma access to healthcare providers is going.
The public said drugmakers spend too much money on marketing to doctors and patients
Initiatives in Europe follow the US example when it comes to requiring manufacturers to report information about financial relationships with physicians.
- Five things for pharma marketers to know: Friday, February 5, 2016
- Why Gathering Health Economic Data for Cancer Drugs is Now Essential
- Ascension Health ups Ragone to chief marcomms officer
- House Oversight committee upbraids Turing, Valeant execs
- Burcin departs Havas network for Klick Health in senior-staffing push